



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

June 2015





HIV/AIDS Drug Treatment Program

Monthly Report

© 2015 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.682.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

June 2015

N = 6910



Health Authority	Male	Female	All
FRASER	1281	386	1667
INTERIOR	341	92	433
NORTHERN	138	77	215
VANCOUVER COASTAL	3340	443	3783
VANCOUVER ISLAND	639	151	790
	5739	1149	6888
		Unknown/not stated:	22
		Total:	6910

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (June 2010 - June 2015)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (June 2010 - June 2015)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (June 2010 - June 2015)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (June 2010 - June 2015)






1.6 Percent Distribution of Active Participants by CD4 Count (June 2010 - June 2015)






1.7 Percent Distribution of Inactive Participants by CD4 Count (June 2010 - June 2015)






1.8 Active and Inactive Participants (June 2010 - June 2015)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (June 2010 - June 2015)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (June 2010 - June 2015)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(June 2010 - June 2015)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (June 2010 - June 2015)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(June 2010 - June 2015)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (June 2010 - June 2015)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(June 2010 - June 2015)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (June 2010 - June 2015)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(June 2010 - June 2015)






1.18 Baseline CD4 for Antiretroviral First Starts
(June 2010 - June 2015)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (June 2010 - June 2015)






1.20 Cumulative Resistance Testing Results by Resistance Category (June 2010 - June 2015)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (June 2010 - June 2015)





2.1 Duration of ARV treatment in the Province of BC, 1987-2015 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	23	5	0	5	5	800	5	<40	4
1988	23	8	0	8	8	450	8	<40	4
1989	22	56	2	58	53	500	57	<40	4
1990	21	63	1	64	59	530	63	<40	4
1991	21	38	3	41	36	550	40	<40	4
1992	21	67	5	72	56	565	71	<40	4
1993	20	147	15	162	146	550	157	<40	4
1994	19	98	13	111	90	535	108	<40	4
1995	18	129	26	155	128	545	149	<40	4
1996	17	379	58	437	375	570	422	<40	4
1997	15	316	39	355	318	580	344	<40	3
1998	14	225	47	272	231	550	265	<40	4
1999	14	185	41	226	183	550	212	<40	3
2000	14	140	39	179	155	560	167	<40	3
2001	14	132	40	172	147	550	166	<40	3
2002	13	137	33	170	143	530	164	<40	3
2003	12	179	34	213	182	590	205	<40	3
2004	11	181	49	230	192	560	220	<40	3
2005	10	213	53	266	228	595	260	<40	4
2006	9	219	49	268	217	530	256	<40	3
2007	8	281	57	338	282	585	324	<40	3
2008	7	324	79	403	336	620	388	<40	3
2009	6	358	75	433	372	625	418	<40	3
2010	5	326	77	403	345	620	390	<40	3
2011	4	372	76	448	390	620	428	<40	3
2012	3	318	72	390	330	630	378	<40	3
2013	2	310	75	385	308	610	371	<40	3
2014	1	330	59	389	326	630	378	<40	3
2015	0	207	32	239	223	510	234	63	4
Total:		5743	1149	6892					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	6557	782	2429	<40	2151	560
FEB-2014	6570	782	1895	<40	1656	550
MAR-2014	6598	788	2156	<40	1927	550
APR-2014	6611	790	2126	<40	1874	560
MAY-2014	6677	769	2119	<40	1887	560
JUN-2014	6644	784	1994	<40	1768	550
JUL-2014	6682	779	2179	<40	1930	550
AUG-2014	6703	774	2026	<40	1806	570
SEP-2014	6730	770	2284	<40	2003	550
OCT-2014	6760	763	2250	<40	1957	570
NOV-2014	6758	760	1920	<40	1706	580
DEC-2014	6771	765	1894	<40	1688	580
JAN-2015	6746	760	2427	<40	2110	580
FEB-2015	6798	753	1980	<40	1728	570
MAR-2015	6845	747	2175	<40	1882	570
APR-2015	6858	739	2147	<40	1872	580
MAY-2015	6899	739	2030	<40	1747	560
JUN-2015	6910	740	2256	<40	1863	580

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	1411	2265	100	6683	76	285
FEB-2014	1432	2150	73	496	67	490
MAR-2014	1434	2154	114	3726	98	340
APR-2014	1444	2140	112	128	90	400
MAY-2014	1415	2305	90	617	76	350
JUN-2014	1468	2047	96	423	82	380
JUL-2014	1460	2111	95	982	76	355
AUG-2014	1452	2158	87	208	72	365
SEP-2014	1452	2177	103	866	89	390
OCT-2014	1440	2247	84	257	62	395
NOV-2014	1453	2233	74	3945	64	400
DEC-2014	1473	2173	93	557	72	340
JAN-2015	1510	2057	105	1364	84	305
FEB-2015	1490	2140	98	74	84	380
MAR-2015	1463	2305	100	66	86	395
APR-2015	1469	2276	82	2279	66	475
MAY-2015	1451	2387	74	135	56	400
JUN-2015	1473	2305	93	115	83	430

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2014	6539	1411	2	30	144	136	35	11494
FEB-2014	6548	1432	9	40	139	159	9	11538
MAR-2014	6573	1434	9	36	151	146	25	11582
APR-2014	6587	1444	5	27	159	161	14	11618
MAY-2014	6646	1415	14	38	191	152	59	11668
JUN-2014	6618	1468	7	24	142	183	-28	11706
JUL-2014	6659	1460	8	34	176	159	41	11750
AUG-2014	6683	1452	6	18	165	149	24	11782
SEP-2014	6713	1452	2	25	168	159	30	11821
OCT-2014	6738	1440	7	21	159	146	25	11848
NOV-2014	6732	1453	12	19	135	144	-6	11872
DEC-2014	6746	1473	7	39	136	148	14	11921
JAN-2015	6713	1510	13	24	148	185	-33	11956
FEB-2015	6769	1490	7	36	189	161	56	12008
MAR-2015	6822	1463	7	30	174	142	53	12049
APR-2015	6827	1469	14	29	170	174	5	12086
MAY-2015	6872	1451	9	33	168	145	45	12127
JUN-2015	6892	1473	4	37	150	163	20	12174

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2014	47	6025	414	71	6557	0.72%	91.89%	6.31%	1.08%	100.00%
FEB-2014	50	6034	418	68	6570	0.76%	91.84%	6.36%	1.04%	100.00%
MAR-2014	50	6054	424	70	6598	0.76%	91.76%	6.43%	1.06%	100.00%
APR-2014	46	6067	422	76	6611	0.70%	91.77%	6.38%	1.15%	100.00%
MAY-2014	47	6138	418	74	6677	0.70%	91.93%	6.26%	1.11%	100.00%
JUN-2014	50	6107	416	71	6644	0.75%	91.92%	6.26%	1.07%	100.00%
JUL-2014	47	6147	415	73	6682	0.70%	91.99%	6.21%	1.09%	100.00%
AUG-2014	47	6170	414	72	6703	0.70%	92.05%	6.18%	1.07%	100.00%
SEP-2014	50	6185	424	71	6730	0.74%	91.90%	6.30%	1.05%	100.00%
OCT-2014	44	6209	434	73	6760	0.65%	91.85%	6.42%	1.08%	100.00%
NOV-2014	47	6217	424	70	6758	0.70%	91.99%	6.27%	1.04%	100.00%
DEC-2014	45	6231	421	74	6771	0.66%	92.02%	6.22%	1.09%	100.00%
JAN-2015	47	6185	440	74	6746	0.70%	91.68%	6.52%	1.10%	100.00%
FEB-2015	45	6228	452	73	6798	0.66%	91.62%	6.65%	1.07%	100.00%
MAR-2015	45	6297	436	67	6845	0.66%	91.99%	6.37%	0.98%	100.00%
APR-2015	43	6312	436	67	6858	0.63%	92.04%	6.36%	0.98%	100.00%
MAY-2015	45	6354	432	68	6899	0.65%	92.10%	6.26%	0.99%	100.00%
JUN-2015	47	6344	447	72	6910	0.68%	91.81%	6.47%	1.04%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	8 19%	2381 37%	7 17%	1994 31%	0 0%	144 2%	0 0%	25 0%	0 0%	17 0%	33 79%	3862 61%	36 86%	4269 67%
FEB-2014	7 16%	2383 37%	7 16%	1992 31%	0 0%	140 2%	0 0%	25 0%	0 0%	16 0%	37 84%	3880 61%	37 84%	4286 67%
MAR-2014	7 16%	2386 37%	6 14%	2007 31%	0 0%	140 2%	0 0%	22 0%	0 0%	13 0%	37 84%	3893 61%	38 86%	4298 67%
APR-2014	3 8%	2396 37%	3 8%	2022 32%	0 0%	137 2%	0 0%	22 0%	0 0%	12 0%	33 92%	3904 61%	33 92%	4301 67%
MAY-2014	17 34%	2434 38%	16 32%	2058 32%	1 2%	137 2%	0 0%	21 0%	0 0%	13 0%	33 66%	3929 61%	33 66%	4325 67%
JUN-2014	8 21%	2431 38%	9 24%	2063 32%	0 0%	130 2%	0 0%	20 0%	1 3%	13 0%	29 76%	3905 61%	29 76%	4293 67%
JUL-2014	13 30%	2462 38%	11 25%	2095 32%	1 2%	129 2%	0 0%	22 0%	0 0%	13 0%	31 70%	3918 60%	32 73%	4298 66%
AUG-2014	7 23%	2474 38%	7 23%	2108 32%	0 0%	132 2%	0 0%	21 0%	0 0%	11 0%	24 77%	3913 60%	24 77%	4287 66%
SEP-2014	15 38%	2517 39%	12 31%	2146 33%	3 8%	136 2%	0 0%	18 0%	0 0%	12 0%	24 62%	3905 60%	24 62%	4285 66%
OCT-2014	10 37%	2546 39%	9 33%	2173 33%	0 0%	134 2%	0 0%	18 0%	0 0%	12 0%	17 63%	3906 60%	17 63%	4287 65%
NOV-2014	6 25%	2548 39%	6 25%	2183 33%	0 0%	129 2%	0 0%	18 0%	0 0%	12 0%	17 71%	3896 59%	19 79%	4269 65%
DEC-2014	13 27%	2576 39%	9 18%	2205 34%	3 6%	129 2%	0 0%	19 0%	0 0%	11 0%	36 73%	3875 59%	37 76%	4247 65%
JAN-2015	10 29%	2585 40%	10 29%	2222 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3850 59%	25 71%	4214 64%
FEB-2015	8 15%	2594 39%	8 15%	2229 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3888 59%	44 85%	4251 64%
MAR-2015	11 27%	2613 39%	11 27%	2256 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 73%	3921 59%	30 73%	4277 64%
APR-2015	11 31%	2631 40%	11 31%	2272 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 67%	3921 59%	24 67%	4277 64%
MAY-2015	8 20%	2645 40%	7 18%	2287 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3936 59%	33 83%	4290 64%
JUN-2015	10 21%	2637 39%	10 21%	2291 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3953 59%	37 79%	4304 64%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	0 0%	19 1%	10 59%	2306 65%	7 41%	738 21%	0 0%	471 13%	0 0%	6 0%	0 0%	3 0%	0 0%	28 1%
FEB-2014	0 0%	19 1%	12 57%	2287 64%	7 33%	761 21%	2 10%	470 13%	0 0%	4 0%	0 0%	2 0%	0 0%	27 1%
MAR-2014	0 0%	18 1%	8 47%	2266 64%	7 41%	788 22%	2 12%	475 13%	0 0%	5 0%	0 0%	2 0%	0 0%	26 1%
APR-2014	0 0%	18 1%	11 52%	2259 63%	10 48%	811 23%	0 0%	468 13%	0 0%	3 0%	0 0%	2 0%	0 0%	26 1%
MAY-2014	0 0%	16 0%	7 41%	2249 64%	9 53%	815 23%	1 6%	456 13%	0 0%	4 0%	0 0%	3 0%	0 0%	25 1%
JUN-2014	0 0%	16 0%	5 31%	2198 63%	9 56%	831 24%	2 13%	449 13%	0 0%	5 0%	0 0%	3 0%	0 0%	25 1%
JUL-2014	0 0%	15 0%	10 59%	2182 63%	6 35%	851 24%	1 6%	433 12%	0 0%	5 0%	0 0%	1 0%	0 0%	26 1%
AUG-2014	0 0%	14 0%	2 20%	2153 62%	8 80%	856 25%	0 0%	425 12%	0 0%	5 0%	0 0%	1 0%	0 0%	24 1%
SEP-2014	0 0%	14 0%	4 31%	2139 62%	6 46%	868 25%	3 23%	424 12%	0 0%	5 0%	0 0%	1 0%	0 0%	21 1%
OCT-2014	0 0%	14 0%	3 30%	2133 62%	5 50%	889 26%	2 20%	407 12%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
NOV-2014	0 0%	15 0%	10 83%	2107 62%	2 17%	893 26%	0 0%	397 12%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
DEC-2014	0 0%	13 0%	7 32%	2075 61%	12 55%	922 27%	3 14%	385 11%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
JAN-2015	0 0%	12 0%	6 50%	2030 60%	6 50%	933 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2032 60%	18 69%	959 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2047 60%	8 47%	968 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 0%
APR-2015	0 0%	12 0%	7 32%	2029 60%	15 68%	985 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	2007 59%	6 38%	1014 30%	0 0%	361 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1970 58%	10 56%	1030 31%	0 0%	359 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2014	0	0%	1	0%
FEB-2014	0	0%	0	0%
MAR-2014	0	0%	1	0%
APR-2014	0	0%	1	0%
MAY-2014	0	0%	1	0%
JUN-2014	0	0%	1	0%
JUL-2014	0	0%	1	0%
AUG-2014	0	0%	1	0%
SEP-2014	0	0%	1	0%
OCT-2014	0	0%	1	0%
NOV-2014	0	0%	1	0%
DEC-2014	0	0%	1	0%
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	12 80%	1342 48%	1 7%	304 11%	0 0%	948 34%	2 13%	233 8%
FEB-2014	12 71%	1343 48%	0 0%	305 11%	0 0%	942 33%	5 29%	244 9%
MAR-2014	10 71%	1320 47%	0 0%	298 11%	0 0%	943 34%	4 29%	253 9%
APR-2014	4 57%	1304 47%	0 0%	302 11%	1 14%	941 34%	2 29%	260 9%
MAY-2014	5 71%	1298 46%	0 0%	299 11%	0 0%	938 34%	2 29%	263 9%
JUN-2014	4 50%	1280 46%	1 13%	303 11%	1 13%	926 34%	2 25%	258 9%
JUL-2014	8 73%	1261 46%	0 0%	304 11%	1 9%	927 34%	2 18%	257 9%
AUG-2014	11 85%	1260 46%	1 8%	304 11%	0 0%	928 34%	1 8%	254 9%
SEP-2014	8 73%	1254 46%	0 0%	300 11%	2 18%	928 34%	1 9%	251 9%
OCT-2014	3 60%	1231 45%	2 40%	306 11%	0 0%	921 34%	0 0%	255 9%
NOV-2014	2 100%	1207 45%	0 0%	302 11%	0 0%	911 34%	0 0%	252 9%
DEC-2014	8 62%	1190 45%	0 0%	304 11%	1 8%	901 34%	4 31%	254 10%
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	901 34%	2 25%	254 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	893 34%	4 50%	251 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	890 34%	1 13%	255 10%
APR-2015	4 67%	1149 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1141 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1136 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	4 31%	13 1%	6 46%	154 13%	0 0%	79 7%	3 23%	926 81%	0 0%	2 0%
FEB-2014	1 17%	19 2%	5 83%	163 14%	0 0%	77 7%	0 0%	939 81%	0 0%	2 0%
MAR-2014	1 8%	31 3%	8 62%	179 15%	0 0%	78 6%	4 31%	947 79%	0 0%	2 0%
APR-2014	4 50%	78 6%	2 25%	198 16%	0 0%	82 7%	2 25%	953 76%	0 0%	2 0%
MAY-2014	16 64%	138 10%	6 24%	220 16%	0 0%	80 6%	3 12%	948 71%	0 0%	1 0%
JUN-2014	7 47%	187 13%	7 47%	237 17%	0 0%	76 5%	1 7%	930 67%	0 0%	2 0%
JUL-2014	10 59%	247 17%	5 29%	253 17%	0 0%	74 5%	2 12%	932 64%	0 0%	2 0%
AUG-2014	6 55%	298 20%	3 27%	268 18%	0 0%	74 5%	2 18%	919 61%	0 0%	2 0%
SEP-2014	7 47%	355 22%	4 27%	281 18%	0 0%	73 5%	4 27%	919 58%	0 0%	1 0%
OCT-2014	7 47%	406 25%	6 40%	309 19%	0 0%	71 4%	2 13%	906 55%	0 0%	1 0%
NOV-2014	5 45%	452 27%	5 45%	325 19%	0 0%	70 4%	1 9%	893 53%	0 0%	1 0%
DEC-2014	11 65%	500 29%	6 35%	336 19%	0 0%	72 4%	0 0%	888 51%	0 0%	1 0%
JAN-2015	13 72%	541 30%	4 22%	350 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	577 31%	8 33%	358 19%	0 0%	74 4%	2 8%	882 48%	0 0%	1 0%
MAR-2015	10 53%	602 32%	5 26%	369 20%	0 0%	69 4%	4 21%	870 47%	0 0%	2 0%
APR-2015	7 50%	632 33%	4 29%	374 20%	2 14%	67 4%	1 7%	863 45%	0 0%	2 0%
MAY-2015	11 65%	667 34%	4 24%	383 20%	1 6%	70 4%	2 12%	864 44%	0 0%	2 0%
JUN-2015	15 56%	713 35%	8 30%	397 20%	0 0%	72 4%	4 15%	876 43%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2014	2572	39.23	2316	35.32	551	8.40	191	2.91	71	1.08	856	13.05
FEB-2014	2555	38.89	2319	35.30	579	8.81	189	2.88	68	1.04	860	13.09
MAR-2014	2560	38.80	2310	35.01	606	9.18	188	2.85	70	1.06	864	13.09
APR-2014	2542	38.45	2288	34.61	653	9.88	192	2.90	76	1.15	860	13.01
MAY-2014	2537	38.00	2275	34.07	739	11.07	193	2.89	74	1.11	859	12.87
JUN-2014	2502	37.66	2246	33.80	782	11.77	183	2.75	71	1.07	860	12.94
JUL-2014	2493	37.31	2235	33.45	840	12.57	191	2.86	73	1.09	850	12.72
AUG-2014	2465	36.77	2232	33.30	890	13.28	186	2.77	72	1.07	858	12.80
SEP-2014	2437	36.21	2221	33.00	946	14.06	187	2.78	71	1.05	868	12.90
OCT-2014	2420	35.80	2190	32.40	1008	14.91	192	2.84	73	1.08	877	12.97
NOV-2014	2422	35.84	2159	31.95	1056	15.63	184	2.72	70	1.04	867	12.83
DEC-2014	2398	35.42	2145	31.68	1104	16.30	185	2.73	74	1.09	865	12.78
JAN-2015	2349	34.82	2125	31.50	1138	16.87	179	2.65	74	1.10	881	13.06
FEB-2015	2366	34.80	2112	31.07	1180	17.36	178	2.62	73	1.07	889	13.08
MAR-2015	2402	35.09	2113	30.87	1207	17.63	185	2.70	67	0.98	871	12.72
APR-2015	2396	34.94	2096	30.56	1244	18.14	184	2.68	67	0.98	871	12.70
MAY-2015	2406	34.87	2096	30.38	1279	18.54	178	2.58	68	0.99	872	12.64
JUN-2015	2371	34.31	2081	30.12	1327	19.20	170	2.46	72	1.04	889	12.87

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2014	30	6	2	9	4	9	300
FEB-2014	40	4	7	10	4	13	316
MAR-2014	36	2	2	9	10	13	405
APR-2014	27	3	6	2	5	10	355
MAY-2014	38	2	4	3	10	18	500
JUN-2014	24	3	1	6	6	7	400
JUL-2014	34	3	7	7	5	13	350
AUG-2014	18	3	1	3	5	6	410
SEP-2014	25	5	3	3	4	9	395
OCT-2014	21	1	4	6	4	5	315
NOV-2014	19	5	1	0	4	8	475
DEC-2014	39	3	5	7	11	13	401
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	30	2	5	5	8	8	393
APR-2015	29	8	3	4	3	11	340
MAY-2015	33	4	6	9	5	8	290
JUN-2015	37	6	2	8	7	12	370

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2014	10028	2579
FEB-2014	10050	2572
MAR-2014	10063	2558
APR-2014	10093	2561
MAY-2014	10117	2555
JUN-2014	10152	2565
JUL-2014	10164	2553
AUG-2014	10213	2587
SEP-2014	10255	2597
OCT-2014	10278	2606
NOV-2014	10309	2628
DEC-2014	10350	2632
JAN-2015	10392	2662
FEB-2015	10438	2669
MAR-2015	10477	2677
APR-2015	10498	2688
MAY-2015	10552	2712
JUN-2015	10640	2760

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
June 2015

N = 6910

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2015

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2015

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2015

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2015

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	35-49	13	15	8
	50+	18	28	12
	Total HSDA:	31	43	20
KOOTENAY BOUNDARY	0-19	1	1	1
	20-34	3	3	1
	35-49	19	25	14
	50+	44	59	35
	Total HSDA:	67	88	51
OKANAGAN	0-19	3	3	2
	20-34	20	21	16
	35-49	90	105	67
	50+	186	269	143
	Total HSDA:	299	398	228
THOMPSON/CARIBOO/ SHUSWAP	0-19	6	6	1
	20-34	17	17	14
	35-49	57	72	45
	50+	92	130	74
	Total HSDA:	172	225	134
Total HA:		569	754	433

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	4
	20-34	40	41	31
	35-49	179	217	134
	50+	340	486	264
Total HA:		569	754	433

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	440	596	341
Female	129	158	92

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	433	52	540	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	16	10
	5 years or more	7	4
	<5 years	8	6
	Total HSDA:	31	20
KOOTENAY BOUNDARY	10 years or more	31	22
	5 years or more	18	14
	<5 years	18	15
	Total HSDA:	67	51
OKANAGAN	10 years or more	158	112
	5 years or more	74	59
	<5 years	67	57
	Total HSDA:	299	228
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	85	58
	5 years or more	36	33
	<5 years	51	43
	Total HSDA:	172	134
Total HA:		569	433

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	290	202
	5 years or more	135	110
	<5 years	144	121
Total HA:		569	433

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	34	46	12	19
KOOTENAY BOUNDARY	59	106	26	40
OKANAGAN	187	637	71	226
THOMPSON/CARIBOO/SHUSWAP	121	403	43	105
Total:	401	1192	152	390

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	1
KOOTENAY BOUNDARY	12
OKANAGAN	38
THOMPSON/CARIBOO/SHUSWAP	41
Total:	92

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	24	25	19
	35-49	119	132	86
	50+	155	212	125
	Total HSDA:	305	376	236
FRASER NORTH	0-19	20	20	3
	20-34	112	113	100
	35-49	359	411	269
	50+	435	679	358
	Total HSDA:	926	1223	730
FRASER SOUTH	0-19	12	12	5
	20-34	92	94	68
	35-49	359	408	296
	50+	395	586	332
	Unknown	0	1	0
	Total HSDA:	858	1101	701
Total HA:		2089	2700	1667

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	39	39	14
	20-34	228	232	187
	35-49	837	951	651
	50+	985	1477	815
	Unknown	0	1	0
Total HA:		2089	2700	1667

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1576	2070	1281
Female	513	630	386

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1667	49	592	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	140	103
	5 years or more	85	67
	<5 years	80	66
	Total HSDA:	305	236
FRASER NORTH	10 years or more	435	321
	5 years or more	228	177
	<5 years	263	232
	Total HSDA:	926	730
FRASER SOUTH	10 years or more	387	304
	5 years or more	229	192
	<5 years	242	205
	Total HSDA:	858	701
Total HA:		2089	1667

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	962	728
5 years or more	542	436
<5 years	585	503
Total HA:	2089	1667

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	124	367	44	73
FRASER NORTH	223	1339	62	268
FRASER SOUTH	198	1147	47	355
Total:	545	2853	153	696

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	183
FRASER NORTH	607
FRASER SOUTH	480
Total:	1270

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	2	2	0
	20-34	20	20	17
	35-49	86	100	66
	50+	193	312	171
	Total HSDA:	301	434	254
RICHMOND	0-19	8	8	2
	20-34	19	19	17
	35-49	46	49	37
	50+	72	111	58
	Total HSDA:	145	187	114
VANCOUVER	0-19	58	61	8
	20-34	405	414	318
	35-49	1641	1922	1244
	50+	2316	3841	1845
	Total HSDA:	4420	6238	3415
Total HA:		4866	6859	3783

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	68	71	10
	20-34	444	453	352
	35-49	1773	2071	1347
	50+	2581	4264	2074
Total HA:		4866	6859	3783

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4274	6027	3340
Female	590	830	443

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3783	50	590	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	165	133
	5 years or more	48	43
	<5 years	88	78
	Total HSDA:	301	254
RICHMOND	10 years or more	69	49
	5 years or more	34	26
	<5 years	42	39
	Total HSDA:	145	114
VANCOUVER	10 years or more	2183	1567
	5 years or more	1090	883
	<5 years	1147	965
	Never on ART	0	0
	Total HSDA:	4420	3415
Total HA:	4866	3783	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2417	1749
	5 years or more	1172	952
	<5 years	1277	1082
	Never on ART	0	0
Total HA:		4866	3783

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	135	356	52	85
RICHMOND	42	268	14	92
VANCOUVER	521	9600	205	5202
Total:	698	10224	271	5379

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	6
RICHMOND	2
VANCOUVER	104
Total:	112

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	2	2	1
	20-34	20	22	15
	35-49	83	97	69
	50+	151	243	121
	Total HSDA:		256	364
NORTH VANCOUVER ISLAND	0-19	2	2	1
	20-34	14	15	11
	35-49	35	39	30
	50+	56	84	45
	Total HSDA:		107	140
SOUTH VANCOUVER ISLAND	0-19	8	8	1
	20-34	43	45	32
	35-49	210	251	167
	50+	368	575	297
	Total HSDA:		629	879
Total HA:		992	1383	790

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	3
	20-34	77	82	58
	35-49	328	387	266
	50+	575	902	463
Total HA:		992	1383	790

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	801	1120	639
Female	191	263	151

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	790	51	460	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	121	93
	5 years or more	63	53
	<5 years	72	60
	Total HSDA:	256	206
NORTH VANCOUVER ISLAND	10 years or more	47	37
	5 years or more	23	20
	<5 years	37	30
	Total HSDA:	107	87
SOUTH VANCOUVER ISLAND	10 years or more	305	214
	5 years or more	155	133
	<5 years	169	150
	Total HSDA:	629	497
Total HA:		992	790

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	473	344
	5 years or more	241	206
	<5 years	278	240
Total HA:		992	790

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	166	523	82	168
NORTH VANCOUVER ISLAND	111	226	46	68
SOUTH VANCOUVER ISLAND	180	1485	47	511
Total:	457	2234	175	747

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	45
NORTH VANCOUVER ISLAND	31
SOUTH VANCOUVER ISLAND	81
Total:	157

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	1	1	0
	20-34	5	6	3
	35-49	17	19	10
	50+	16	21	10
	Total HSDA:	39	47	23
NORTH WEST	0-19	2	2	0
	20-34	7	11	6
	35-49	26	39	24
	50+	29	43	23
	Total HSDA:	64	95	53
NORTHERN INTERIOR	0-19	2	2	1
	20-34	29	32	20
	35-49	75	91	60
	50+	71	116	58
	Total HSDA:	177	241	139
Total HA:		280	383	215

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	1
	20-34	41	49	29
	35-49	118	149	94
	50+	116	180	91
Total HA:		280	383	215

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	177	245	138
Female	103	138	77

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	215	47	500	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	13	6
	5 years or more	10	7
	<5 years	16	10
	Total HSDA:	39	23
NORTH WEST	10 years or more	16	8
	5 years or more	22	20
	<5 years	26	25
	Total HSDA:	64	53
NORTHERN INTERIOR	10 years or more	48	30
	5 years or more	48	42
	<5 years	81	67
	Total HSDA:	177	139
Total HA:		280	215

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	77	44
	5 years or more	80	69
	<5 years	123	102
Total HA:		280	215

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	29	55	6	9
NORTH WEST	60	139	19	26
NORTHERN INTERIOR	95	372	23	180
Total:	184	566	48	215

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	18
NORTHERN INTERIOR	20
Total:	44

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	7	10	5
	KOOTENAY BOUNDARY	3	6	3
	OKANAGAN	15	28	8
	THOMPSON/CARIBOO/SHUSWAP	22	37	19
	Total HA:	47	81	35
FRASER	FRASER EAST	33	41	28
	FRASER NORTH	60	89	46
	FRASER SOUTH	67	93	52
	Total HA:	160	223	126
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	23	42	19
	RICHMOND	9	14	6
	VANCOUVER	493	766	422
	Total HA:	525	822	447
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	45	70	34
	NORTH VANCOUVER ISLAND	13	22	13
	SOUTH VANCOUVER ISLAND	33	70	28
	Total HA:	91	162	75
NORTHERN	NORTH EAST	9	11	4
	NORTH WEST	31	54	29
	NORTHERN INTERIOR	64	94	60
	Total HA:	104	159	93
Total:		927	1447	776

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	590	934	491
Female	337	513	285

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	776	48	460	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: Persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Combination Therapy: using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

Complera (CPL): the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.





Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (DTG): an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

Efavirenz (Sustiva, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

Emtricitabine (FTC): a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

Famciclovir (Famvir): a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: Persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.





Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (MVC, Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: The net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).





Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

Tenofovir (Viread, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Trizivir (TRZ): ViiV Healthcare's trade name for a pill that combines ABACAVIR (ABC), ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

Truvada (TRU): the Gilead trade name for a pill that contains both TENOFOVIR and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

